1 / 17

DIAN Treatment Trials An Update Sunday February 10, 2013

DIAN Treatment Trials An Update Sunday February 10, 2013 . 4:00 to 6:00 PM CST Presented by Randall Bateman MD DIAN Therapeutic Trials Unit Director DIAN Clinical Core Leader Question and Answer Session. Agenda DIAN TU. Introductions Questions and Answers

merrill
Télécharger la présentation

DIAN Treatment Trials An Update Sunday February 10, 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DIAN Treatment Trials An Update Sunday February 10, 2013 4:00 to 6:00 PM CST Presented by Randall Bateman MD DIAN Therapeutic Trials Unit Director DIAN Clinical Core Leader Question and Answer Session

  2. AgendaDIAN TU Introductions Questions and Answers From DIAN participants DIAN Therapeutic Trials

  3. Inclusion/Exclusion Criteria • 15 years before parental age of onset to10 years after parental age of onset • Participants include individuals without impairment but includes; • People with possible symptomatic, or mild dementia • Greater than 18 years of age

  4. Inclusion/Exclusion Criteria • Stage of Disease • Normal • Mildly Symptomatic • Mutation Status • Not required to be known • If you know you are negative you are not eligible

  5. Placebo • FDA requirement • Intravenous or sub cutaneous injection of placebo. • Will have no side effects • In this trial 75%people will receive Treatment • 25%will be placebo including all negative participants

  6. Randomization

  7. Study Drugs Solanezumab and Gantenerumab • Monoclonal antibodies that bind to beta amyloid. • Passive immunization. • Modify early changes in the brain caused by beta amyloid.

  8. Side Effects • Solanezumabgiven by IV or intravenous infusion for 30 minutes you are observed for 2 hours after to watch for side effects. • Anything unusual or usual you experience will be documented • Major side effects: • Increased Water Content of the Brain tissue and • Increase in Small Bleeds in the Brain Tissue (micro-hemorrhage) Brain MRIs are required every 3 months.

  9. Side Effects • Gantenerumab is given subcutaneously, just under the skin on the abdomen. You are watched for 2 hours after for any reaction. • Anything unusual or usual you experience will be documented. • Major side effects: • Increased Water Content of the Brain • Increase in Small Bleeds in the Brain Tissue (micro-hemorrhage(micro-hemmorhage), requires an MRI every 3 months.

  10. Study Visits • At Home Screening Visit (V01) screening • Initial Baseline Visit (V02) screening and Complete Assessment • Once a month at your home or near where you live • Every 3 Month MRI near where you live • Annual Baseline Visit Complete Assessment

  11. Study Visits

  12. Baseline Visit At the baseline visit, the screening process will determine eligibility, and biomarker studies completed. Specifically, you will be asked to complete: • A screening EKG • to look for any cardiac (heart) abnormalities. • An MRI • which looks at the structure of the brain. • Three PET scans • scheduled over the entire visit. Each PET scan uses a small amount of a radioactive tracer to observe either the energy use of the brain or the presence of amyloid plaques. • A lumbar puncture • for collection of cerebrospinal fluid.

  13. Baseline Visit continued: • A clinical evaluation with a study clinician • to assess for changes in memory and thinking, judgment, personality and mood. The clinical will also complete a physical and neurologic exam. • Paper-pencil and computerized testing • to assess your memory and thinking abilities. • Blood sampling • to determine if there are certain markers in the blood (and if so how much) that might indicate the presence of disease.

  14. Baseline Visit continued • Blood sampling for genetic testing. • Your blood will be sent to a study approved lab using a unique ID number to test for the reported family mutation. You will not receive the results of this testing. If, during your study participation, you wish to learn your mutation status, the study team will refer you to a certified genetic counselor.

  15. Baseline Visit Schedule

  16. FAQs • Weekend Treatments? Yes we hope to negotiate weekend treatments. • How long is the Trial? The first part of the trial is two years. Depending on the success of the drugs it may last longer. • Can you tell if the drug is working? Many of the side effects may not be unusual for you to experience e.g. Headache and Nausea. Everything will be reported to your nurse. • Do you keep taking your regular medication? Yes but the medication should stay the same.

  17. FAQs • When will trials begin? The Washington University site has begun recruitment. • Do I participate at my DIAN Site? Yes, preferably

More Related